Recent research has shed new light on multiple sclerosis (MS) in children, who make up about 3% to 5% of the MS population. At one time, children were thought to not experience disability due to their ...

Early treatment of pediatric-onset relapsing-remitting multiple sclerosis (MS) with high-efficacy therapy (HET) is associated with substantially slower disability progression than treatment with ...

The Jacobs Neurological Institute at UB has received a $1.8 million, five-year grant from the National Multiple Sclerosis Society to establish at Women and Children's Hospital of Buffalo one of six ...

Please provide your email address to receive an email when new articles are posted on . Risk of treatment discontinuation at 2 years was six times higher with moderately effective therapies. Highly ...

Please provide your email address to receive an email when new articles are posted on . Children presented with unique MS symptoms, while adolescents’ issues aligned more with adults. Nearly half of ...

Rates of autoimmune diseases, including thyroid disorders and multiple sclerosis (MS), are higher among families of patients with pediatric MS compared with unaffected families, new research suggests.

Pediatric-onset MS (POMS) is more inflammatory than adult-onset MS, with frequent relapses and cognitive issues, affecting 7.6% of MS cases. The 2017 McDonald criteria improved POMS diagnostic ...

Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya ® (fingolimod) vs. interferon beta-1a, in children and adolescents ...

Children living with multiple sclerosis (MS) show signs of accelerated biological aging, even in their teenage years. This is according to new research from scientists at the University of California ...

After 96 weeks, there was no difference in time to first clinical relapse of multiple sclerosis with teriflunomide compared with placebo. Teriflunomide was well tolerated - serious adverse events ...

While diagnostic criteria for typical multiple sclerosis (MS) perform well in people ages 18 to 50, differential diagnoses in pediatric-onset MS and late-onset MS require specific considerations.